StockIQpro
NASDAQ:CADL

Candel Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Candel Therapeutics, Inc. reported net income of −$38.2M in fiscal 2025. Free cash flow was −$38.9M, and the diluted share count rose 67.2%.Summary generated from Candel Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−64.6%
Debt / equityn/a
Free cash flow−$38.9M
FCF marginn/a
Share count change+67.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue00n/an/an/a
Operating income−26−35−38−33−48
Net income−36−19−38−55−38
Free cash flow−24−33−35−27−39

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)